A review of the newer antiepileptic drugs and the ketogenic diet

Clinical Pediatrics

Volumn 36, Issue 9, 1997, Pages 513-521

  Barron, Todd F ^a   Hunt, Sarah L ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ANTICONVULSIVE AGENT; CARBAMAZEPINE; FELBAMATE; GABAPENTIN; LAMOTRIGINE; PHENYTOIN; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ANOREXIA; ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; ARTICLE; ATAXIA; CLINICAL TRIAL; DIET THERAPY; DIPLOPIA; DRUG CHOICE; DRUG SAFETY; EPILEPSY; HUMAN; INSOMNIA; ORAL DRUG ADMINISTRATION; RASH; SOMNOLENCE; THROMBOCYTOPENIA; VERTIGO; VOMITING;

EID: 0030846813     PISSN: 00099228     EISSN: None     Source Type: Journal    
DOI: 10.1177/000992289703600904     Document Type: Article

References (61)

1. Engel J Jr. Classifications. In: Seizures and Epilepsy. Engel J, ed. Philadelphia: F.A. Davis Company; 1989.
2. Leppik IE. Felbamate. Epilepsia. 1995;36(Suppl 2):S66-72.
3. DeGiorgio CM, Lopez JE, Lekht ZN, et al. Status epilepticus induced by Felbatol withdrawal. Neurology. 1995; 45:1021-1022.
4. Albani F, Theodore WH, Washington P, et al. Effect of felbamate on plasma levels of carbamazepine and its metabolites. Epilepsia. 1995;32:130-132.
5. Fuerst RH, Graves NM, Leppik IE, et al. Felbamate increases phenytoin but decreases carbamazepine concentrations. Epilepsia. 1988;29:488-491.
6. Wagner ML, Graves NM, Leppik IE. The effect of felbamate on valproic acid disposition. Abstract presented at the American Epilepsy Society Meeting in Philadelphia. December 1991.
7. Wagner ML, Leppik EI, Graves NM, et al. Felbamate serum concentrations; effect of valproate, carbamazepine, phenytoin and phenobarbital. Epilepsia. 1990;31:642.
8. Saano V, Glue P, Banfield CR, et al. Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive. Clin Pharmacol Ther. 1995;58:523-531.
9. Faught E, Sachdeo RC, Remler MP, et al. Felbamate monotherapy for partial-onset seizures. Neurology. 1993;43: 688-692.
10. Sachdeo R, Kramer LD, Rosenberg A, et al. Felbamate monotherapy: controlled trial in patients with partial onset seizures. Ann Neurol. 1992;32:386-392.
11. Pennell PB, Ogaily MS, Macdonald RL. Aplastic anemia in patient receiving felbamate for complex partial seizures. Neurology. 1995;45:456-460.
12. Felbatol: Clinical update. Wallace Laboratories, 1995.
13. Goa KL, Sorkin EM. Gabapentin. Drugs. 1993;46:409-427.
14. McLean MJ. Clinical pharmacokinetics of gabapentin. Neurology. 1994;44 (Suppl 5):S17-S22.
15. Bourgeois BFD. Antiepileptic drugs in pediatric practice. Epilepsia. 1995;36 (Suppl 2):S34-S45.
16. McLean MJ. Gabapentin. Epilepsia. 1995;36(Suppl 2):S73-S86.
17. Litzinger MJ, Wiscombe N, Hanny A. Increased seizures and aggression seen in persons with mental retardation and epilepsy treated with neurontin. Epilepsia. 1995;36(Suppl 4):S73.
18. Asconapé J, Collins T. Weight gain associated with the use of gabapentin. Epilepsia. 1995;36(Suppl 4):S74.
19. King J, Bayles RL. Weight gain during and-on therapy using gabapentin (GBP). Epilepsia. 1995;36(Suppl 4):S74.
20. Cugley AL, Swartz BE. Gabapentin-associated mood changes. Epilepsia. 1995;36(Suppl 4):S74.
21. Shantz D, Towbin JA, Spitz MC. Changes in mood and affect in patients on gabapentin. Epilepsia. 1995;36(Suppl 4):S75.
22. Zupanc ML, Schroeder VM. Behavioral changes in children on gabapentin. Epilepsia. 1995;36(Suppl 4):S75.
23. Anhut H, Greiner MJ, Murray GH. Double-blind, fixed-dose comparison study of gabapentin (GBP;Neurontin) and carbamazepine (CBZ) monotherapy in patients with newly diagnosed partial epilepsy. Epilepsia. 1995;36 (Suppl 4):S67.
24. Hes MS, Trudeau VL, Kilgore MB, et al. A double-blind, placebo-controlled, randomized multicenter trial of gabapentin (GBP:Neurontin) in pediatric patients with benign childhood epilepsy with centrotemporal spikes (BECTS). Epilepsia. 1995;36 (Suppl 4):S125.
25. Tatum WO, Zachariah SB. Gabapentin treatment of seizures in acute intermittent porphyria. Neurology. 1995;45:1216-1217.
26. Krauss GL, Simmons-O'Brien E, Campbell M. Successful treatment of seizures and porphyria with gabapentin. Neurology. 1995;45:594-595.
27. Leiderman D, Garofalo E, LaMoreaux L. Gabapentin patients with absence seizures: two double-blind, placebo controlled studies. Epilepsia. 1993;34 (Suppl 6):S45.
28. Messenheimer JA. Lamotrigine. Clin Neuropharmacol. 1994;17:548-559.
29. Timmings PL, Richens A. Lamotrigine as an add-on drug in the management of Lennox-Gastaut syndrome. Eur Neurol. 1992;32:305-307.
30. Strumia S, Hirsch E, Moszkowski J, et al. Lamotrigine effect in typical absences. Epilepsia. 1994;35(Suppl 8):S118.
31. Philbrook B, Martinez OA, Callerame KJ. Efficacy of lamotrigine in patients with primary generalized epilepsy: a retrospective study. Epilepsia. 1995;36 (Suppl 4):S66.
32. Weatherford KJ, Campbell LR, Ahmann PA, et al. Lamotrigine in primary generalized epilepsy. Epilepsia. 1995;36(Suppl 4):S67.
33. Brodie MJ, Richens A, Yuen AWC, et al. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet. 1995;345: 476-479.
34. Chapman A, Yuen AWC. Lamotrigine (Lamictal) versus carbamazepine as monotherapy in patients with epilepsy. Epilepsia. 1994;35(Suppl 7):S69.
35. Faught ER, Leroy RF, Messenheimer JA, et al. Clinical experience with lamotrigine (Lamictal) monotherapy for partial seizures in adult outpatients. Epilepsia. 1992;33(Suppl 3):S82.
36. Heller AJ, Chesterman P, Elwes RDC, et al. Monotherapy for newly diagnosed adult epilepsy: a comparative trial and prognostic evaluation. Epilepsia. 1989;30:648.
37. Steiner J, Yuen AWC. Comparison of lamotrigine and phenytoin monotherapy in newly diagnosed epilepsy. Epilepsia. 1994;35(Suppl 8):S31.
38. Coa KL, Ross SR, Chrisp P. Lamotrigine. Drugs. 1993;46:152-176.
39. Russo M, Li LM, O'Donoghue F, et al. Cutaneous rash with lamotrigine and concomitant valproate therapy. Epilepsia. 1994;35(Suppl 7):S72.
40. Messenheimer JA. Lamotrigine. Epilepsia. 1995;36(Suppl 2):S87-S95.
41. Wohlfarth R, Saar J, Reinshagen G. Behavioral effects of lamotrigine. Epilepsia. 1994;35(Suppl 7):S72.
42. Smith D, Baker GA, Dewey M, et al. Lamotrigine-induced well-being in epilepsy: antiepileptic or psychotropic effect. Epilepsia. 1991;32(Suppl 1):S59.
43. Holdich T, Whiteman P, Orme M et al. Effect of lamotrigine on the pharmacology of the combined oral contraceptive pill. Epilepsia. 1991;32(Suppl 1):S96.
44. Schlumberger E, Chavez F, Palacios L et al. Lamotrigine in treatment of 120 children with epilepsy. Epilepsia. 1994;35:359-367.
45. Dulac O, Withers RM, Yuen AWC. Add-on lamotrigine in pediatric patients with treatment-resistant epilepsy. Epilepsia. 1991;32(Suppl 1):S95.
46. Wallace SJ. Add-on open trial of lamotrigine in resistant childhood seizures. Abstract. Brain and Development. 1990;12:734.
47. Battino D, Buti D, Croci D et al. Lamotrigine in resistant childhood epilepsy. Neuropediatrics. 1993;24:332-336.
48. Uldall P, Hansen FJ, Tonnby B. Lamotrigine in Rett syndrome. Neuropediatrics. 1993;24:339-340.
49. Kurland AH, Browne TR. Vigabatrin (Sabril): review. Clin Neuropharmacol. 1994;17:560-568.
50. Chiron C, Dulac O, Beaumont D, et al. Therapeutic trail of vigabatrin in refractory infantile spasms. J Child Neurol. 1991;6:52-59.
51. Vles JSH, van der Heyden HG, Ghijs A, et al. Vigabatrin in the treatment of infantile spasms. Neuropediatrics. 1993; 24:230-231.
52. Aicardi J. Vigabatrin (VGB) as first-line monotherapy in infantile spasms. Epilepsia. 1995;36(Suppl 4):S832.
53. Reife R. Topiramate. In: Sharvon SD, ed. The Treatment of Epilepsy. Cambridge, MA: Blackwell Science; 1996.
54. Espe-Lillo J, Ritter FJ, Frost MD, et al. Safety and efficacy of topiramate in pediatric subjects. Epilepsia. 1994;35 (Suppl 8):S162.
55. Thanedar S, Rosenfeld WE. Topiramate well tolerated by pediatric patients. Epilepsia. 1995;36(Suppl 4): S34.
56. Espe-Lillo J, Ritter FJ, Frost MD, et al. Topiramate in childhood epilepsy: titration, adverse events, and efficacy in multiple seizure types. Epilepsia. 1995;36(Suppl 4):S56.
57. French JA, Bourgeois BFD, Dreifus FE, et al. An open-label multicenter study of topiramate in patients with the Lennox-Gastaut syndrome. Neurology. 1995;45(Suppl 4):250.
58. Rosenfeld WE, Doose DR, Walker SA, et al. Steady-state pharmacokinetics of topiramate as adjunctive therapy in pediatric subjects with epilepsy. Epilepsia. 1995;36(Suppl 3):S158.
59. Kinsman SL, Vining EPG, Quaskey SA. Efficacy of the ketogenic diet for intractable seizure disorders; Review of 58 cases. Epilepsia. 1992;33:1132-1136.
60. Freeman JM, Kelly MT, Freeman JB. The Epilepsy Diet Treatment: An Introduction to the Ketogenic Diet. New York: Demos Publications; 1994.
61. Hunt SL, Barron TF, Frankenfeld N. Use of carbohydrate free formula in the ketogenic diet. Epilepsia. 1995;36 (Suppl 4):S127.